Graft Polymer PLC: Unique opportunity in polymer modification
Last updated: 17:11 20 Sep 2022 AEST, First published: 17:09 20 Sep 2022 AEST
|
Graft Polymer (UK) PLC (LON:GPL) is focused on the development and commercial production of modified polymers, biological supplements and nano-drug delivery systems. The group was founded in 2017 to commercialise the accumulated technological experience gained through previously implemented projects. The focus is on exploiting opportunities that large participants in the market are less capable of delivering. It has been a busy year for the group, starting with its listing on the Main Market of the LSE in January that raised £4.15mln (net) in the process. Five patents have been granted to the company across different jurisdictions and Graft Polymer has gained the requisite certification in Slovenia which will enable it to enter the B2C market. Graft Polymer's IP was effectively showcased in successful clinical trials by MGC Pharmaceuticals. Pre-payments have made on tailor-made equipment which will double Graft Polymer's production capacities. Finally, the company has recently announced it is now cash flow positive at its facility in Slovenia. We highlight the following points on the investment case:
|
Proactive Investors Australia Pty Ltd ACN 132 787 654 (the Company, we or us) provides you with access to the content set out above, including any news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) and this website (the Site) on the terms set out in this disclaimer, together with all other terms and conditions, disclaimers and other notices displayed elsewhere on this Site.
It is important for you to know that:
(a) none of the Content is, or is intended to be, general or personal advice
(b) the principal purpose of the Content is to provide factual information only and to comment on news;
(c) the Content does not contain or imply any recommendation or opinion intended to influence your financial decisions, including in respect of any particular security, portfolio of securities, transaction or investment strategy, and must not be relied upon by you as such;
(d) in providing you with the Content, we have not considered your objectives, financial situation or needs; and
(e) you should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
The Content contains data (including but not limited to prices, statistics and calculated information) obtained from a variety of third party sources (Third Party Data). The Company does not make any representation or warranty that any of the Content, including the Third Party Data, will be reliable, accurate or complete. The Company disclaims all responsibility and liability arising in any way from any errors or omissions in the Content, including the Third Party Data, including any loss you may incur in connection with any action or decision made by you in reliance upon the Content or Third Party Data.
In certain circumstances the Company, its related bodies corporate, or their affiliates, may have received, or be entitled to receive, financial or other consideration in connection with providing information about certain entities on the Site, which may include the above Content.
FOR OUR FULL DISCLAIMER CLICK HEREThis document is published by Proactive Research and its contents have not been approved as a financial promotion by Proactive Investors Limited or any other FCA authorised person. This communication is made on the basis of the 'journalist exemption' provide for in Article 20 of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and having regard to the FCA rules, and in particular PERG 8.12.
Where the note contains a ‘buy, sell, hold’ recommend, Proactive Investors Limited is authorised to provide investment advice as defined by Article 53 of the RAO
FOR OUR FULL DISCLAIMER CLICK HERE